https://www.us.pluvicto.com/and (without the hype)
https://www.nejm.org/doi/full/10.1056/nejmoa2107322or (if you don't want to dig into the details):
ConclusionsRadioligand therapy with 177Lu-PSMA-617 prolonged imaging-based progression-free survival and overall survival when added to standard care in patients with advanced PSMA-positive metastatic castration-resistant prostate cancer.Post Edited (Sr Sailor) : 4/21/2022 1:17:11 PM (GMT-6)